



Matthias Schwenkglenks

Contact

Matthias Schwenkglenks

Publications (15)

Moutzouri E, Glutz M, Abolhassani N, Feller M, Adam L, Gencer B, Del Giovane C, Bétrisey S, Paladini R, Hennings E, Aeschbacher S, Beer J, Moschovitis G, Seiffge D, De Marchis G, Coslovsky M, Reichlin T, Conte G, Sinnecker T, Schwenkglenks M, Bonati L, Kästner P, Aujesky D, Kühne M, Osswald S, Fischer U, Conen D, Rodondi N. Association of statin use and lipid levels with cerebral microbleeds and intracranial hemorrhage in patients with atrial fibrillation: A prospective cohort study. *Int J Stroke* 2023;17474930231181010.

Kühne M, Krisai P, Coslovsky M, Rodondi N, Müller A, Beer J, Ammann P, Auricchio A, Moschovitis G, Hayoz D, Kobza R, Shah D, Stephan F, Schläpfer J, Di Valentino M, Aeschbacher S, Ehret G, Eken C, Monsch A, Roten L, Schwenkglenks M, Springer A, Sticherling C, Reichlin T, Zuern C, Meyre P, Blum S, Sinnecker T, Würfel J, Bonati L, Conen D, Osswald S, Swiss-AF Investigators. Silent brain infarcts impact on cognitive function in atrial fibrillation. *Eur Heart J* 2022; 43:2127–2135.

Girod M, Coslovsky M, Aeschbacher S, Sticherling C, Reichlin T, Roten L, Rodondi N, Ammann P, Auricchio A, Moschovitis G, Kobza R, Badertscher P, Knecht S, Krisai P, Marugg A, Aebersold H, Hennings E, Serra-Burriel M, Schwenkglenks M, Zuern C, Bonati L, Conen D, Osswald S, Kühne M. Association of pulmonary vein isolation and major cardiovascular events in patients with atrial fibrillation. *Clin Res Cardiol* 2022; 111:1048–1056.

Stoffel S, Lupatsch J, Schwenkglenks M, Dietrich D, Schär C, Feller A, Anchisi S, von Briel T, Zürrer-Härdi U, Gillessen S, Cathomas R, Thürlimann B, von Moos R, Mark M. Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland – the SAKK 95/16 prostate study. *Swiss Med Wkly* 2021; 151:w20464.

Meyre P, Osswald S, Conen D, Kühne M, Schwenkglenks M, Sticherling C, Bonati L, Meyer-Zürn C, Mathys R, Blum M, Ammann P, Di Valentino M, Beer J, Rodondi N, Blum S, Aeschbacher S, Springer A, Swiss-AF Investigators. Association of psychosocial factors with all-cause hospitalizations in patients with atrial fibrillation. *Clin Cardiol* 2020; 44:51–57.

Polymeris A, Coslovsky M, Aeschbacher S, Sinnecker T, Benkert P, Kobza R, Beer H, Rodondi N, Fischer U, Moschovitis G, Monsch A, Springer A, Schwenkglenks M, Wuerfel J, De Marchis G, Lyrer P, Kühne M, Osswald S, Conen D, Kuhle J, Bonati L, and for the Swiss-AF Investigators. Serum neurofilament light in atrial fibrillation: clinical, neuroimaging and cognitive correlates. *Brain Commun* 2020; 2:fcaa166.

Bhadhuri A, Insinga R, Guggisberg P, Panje C, Schwenkglenks M. Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland. *Swiss Med Wkly* 2019; 149:w20170.

Blum S, Schläpfer J, Henz S, Meyer-Zürn C, Roten L, Schwenkglenks M, Sticherling C, Kühne M, Osswald S, Conen D, Shah D, Di Valentino M, Moschovitis G, Aeschbacher S, Meyre P, Zwimpfer L, Reichlin T, Beer J, Ammann P, Auricchio A, Kobza R, Erne P, Swiss-AF Investigators. Incidence and Predictors of Atrial Fibrillation Progression. *J Am Heart Assoc* 2019; 8:e012554.

Conen D, Sticherling C, Bonati L, Ehret G, Moutzouri E, Fischer U, Monsch A, Stippich C, Wuerfel J, Sinnecker T, Coslovsky M, Schwenkglenks M, Kühne M, Osswald S, Meyre P, Blum S, Rodondi N, Müller A, Beer J, Ammann P, Moschovitis G, Auricchio A, Hayoz D, Kobza R, Shah D, Novak J, Schläpfer J, Di Valentino M, Aeschbacher S, Swiss-AF Study Investigators. Relationships of Overt and Silent Brain Lesions With Cognitive Function in Patients With Atrial Fibrillation. *J Am Coll Cardiol* 2019; 73:989–999.

Panje C, Lupatsch J, Plasswilm L, Aebersold D, Siano M, Gautschi O, Schwenkglenks M, Matter-Walstra K, Dedes K, Swiss Group for Clinical Cancer Research (SAKK). A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC). *Radiother Oncol* 2018; 129:257–263.

Conen D, Sticherling C, Bonati L, Ehret G, Roten L, Fischer U, Monsch A, Stippich C, Wuerfel J, Schwenkglenks M, Kuehne M, Erne P, Di Valentino M, Novak J, Rodondi N, Mueller A, Beer J, Auricchio A, Ammann P, Hayoz D, Kobza R, Moschovitis G, Shah D, Schlaepfer J, Osswald S. Design of the Swiss Atrial Fibrillation Cohort Study (Swiss-AF): structural brain damage and cognitive decline among patients with atrial fibrillation. *Swiss Med Wkly* 2017; 147:w14467.

Jürgens V, ess s, Schwenkglenks M, Cerny T, Vounatsou P. Using lung cancer mortality to indirectly approximate smoking patterns in space. *Spat Spatiotemporal Epidemiol* 2015; 14-15:23–31.

Jürgens V, ess s, Phuleria H, Früh M, Schwenkglenks M, Frick H, Cerny T, Vounatsou P. Tobacco-related cancer mortality: projections for different geographical regions in Switzerland. *Swiss Med Wkly* 2013; 143:w13771.

Jürgens V, ess s, Phuleria H, Früh M, Schwenkglenks M, Frick H, Cerny T, Vounatsou P. Bayesian spatio-temporal modelling of tobacco-related cancer mortality in Switzerland. *Geospat Health* 2013; 7:219–36.

Matter-Walstra K, Jörger M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M. Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system. *Value Health* 2011; 15:65–71.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch